Critical Appraisal of Polygenic Risk Scores and Circulating Proteins for Screening, Risk Stratification and Individual Risk Prediction
Thursday, January 28, 2027 at 4:10 PM to 4:40 PM · 30 min. (Europe/London)
Pharmacogenomics & Patient Stratification Stage
Day 2 - Thursday 28th January
Polygenic Risk ScoresPrecision Medicine
Information
- Defining the differences between screening, risk stratification and individual risk prediction, and why these distinctions matter in clinical practice.
- How the performance of polygenic risk scores (PRS) and circulating protein biomarkers should be evaluated, including the key measures of clinical utility.
- Reviewing the evidence for PRS and proteomics in predicting common diseases, highlighting both their strengths and limitations.
- Comparing genomic and proteomic risk prediction with alternative approaches to disease prevention, and discussing where these technologies currently add value—and where they do not.
- Exploring what evidence is still needed before PRS and circulating proteins can be routinely adopted for population screening and personalised prevention.
